$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417027650 Filed on May 15, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q4
Revenue	$88.00K	$68.00K	$70.00K
YoY Change	-43.95%	-71.67%	-91.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.290M	$6.940M	$4.490M
YoY Change	-18.24%	62.15%	-39.65%
% of Gross Profit
Research & Development	$5.466M	$5.035M	$16.83M
YoY Change	-37.27%	-62.54%	-62.44%
% of Gross Profit
Depreciation & Amortization	$44.00K	$56.00K	$50.00K
YoY Change	-34.33%	330.77%	150.0%
% of Gross Profit
Operating Expenses	$5.466M	$5.035M	$21.32M
YoY Change	-37.27%	-71.59%	-59.2%
Operating Profit	-$10.67M
YoY Change	-29.01%
Interest Expense	$1.308M	$1.194M	-$3.060M
YoY Change	79.42%	66.3%	-111.2%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change			-100.0%
Pretax Income	-$10.25M	-$12.62M	-$30.71M
YoY Change	-27.72%	106.55%	27.53%
Income Tax
% Of Pretax Income
Net Earnings	-$10.25M	-$12.62M	-$30.71M
YoY Change	-27.67%	106.68%	27.54%
Net Earnings / Revenue	-11651.14%	-18558.82%	-43871.43%
Basic Earnings Per Share
Diluted Earnings Per Share	-$49.17K	-$78.14K	-$240.3K
COMMON SHARES
Basic Shares Outstanding	191.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.00K	$1.840M	$6.190M
YoY Change	-99.07%	-84.26%	-71.62%
Cash & Equivalents	$22.00K	$2.232M	$6.871M
Short-Term Investments
Other Short-Term Assets	$800.0K	$1.320M	$1.700M
YoY Change	-65.96%	-27.47%	-25.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$820.0K	$3.160M	$7.884M
YoY Change	-81.78%	-76.59%	-67.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.45M	$45.03M	$315.0K
YoY Change	-0.94%	-6.89%	-33.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$120.0K	$130.0K	$148.0K
YoY Change	-45.45%	-15.03%	-22.11%
Total Long-Term Assets	$46.56M	$45.16M	$45.02M
YoY Change	-1.16%	-7.33%	-3.58%
TOTAL ASSETS
Total Short-Term Assets	$820.0K	$3.160M	$7.884M
Total Long-Term Assets	$46.56M	$45.16M	$45.02M
Total Assets	$47.38M	$48.31M	$52.91M
YoY Change	-8.2%	-22.36%	-25.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$37.52M	$12.86M	$12.38M
YoY Change	88.64%	47.38%	5.61%
Accrued Expenses		$933.0K	$901.0K
YoY Change		-21.53%	-31.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.760M
YoY Change	-100.0%	-100.0%	196.77%
Long-Term Debt Due	$17.44M	$25.27M	$20.75M
YoY Change	65.78%	126.84%	83.14%
Total Short-Term Liabilities	$72.79M	$81.91M	$76.41M
YoY Change	21.52%	41.68%	17.93%
LONG-TERM LIABILITIES
Long-Term Debt	$9.840M	$3.050M	$3.000M
YoY Change	-7.87%	-71.25%	-71.54%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$9.840M	$3.047M	$3.000M
YoY Change	-7.87%	-71.28%	-71.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$72.79M	$81.91M	$76.41M
Total Long-Term Liabilities	$9.840M	$3.047M	$3.000M
Total Liabilities	$82.63M	$84.95M	$79.41M
YoY Change	17.07%	24.16%	5.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$689.9M	$687.1M
YoY Change			8.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$35.24M	-$36.64M	-$26.50M
YoY Change
Total Liabilities & Shareholders Equity	$47.38M	$48.31M	$52.91M
YoY Change	-8.2%	-22.37%	-25.27%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q4
OPERATING ACTIVITIES
Net Income	-$10.25M	-$12.62M	-$30.71M
YoY Change	-27.67%	106.68%	27.54%
Depreciation, Depletion And Amortization	$44.00K	$56.00K	$50.00K
YoY Change	-34.33%	330.77%	150.0%
Cash From Operating Activities	-$3.700M	-$12.28M	-$14.09M
YoY Change	-73.94%	-30.19%	-39.35%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$0.00	-$170.0K
YoY Change	-99.38%	-100.0%	-93.8%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$220.0K
YoY Change
Cash From Investing Activities	-$10.00K	$218.0K	-$170.0K
YoY Change	-99.38%	-109.05%	-93.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$360.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.850M	$8.048M	17.49M
YoY Change	-1.28%	-12.94%	-57.72%
NET CHANGE
Cash From Operating Activities	-3.700M	-$12.28M	-14.09M
Cash From Investing Activities	-10.00K	$218.0K	-170.0K
Cash From Financing Activities	3.850M	$8.048M	17.49M
Net Change In Cash	140.0K	-$4.017M	3.230M
YoY Change	-101.17%	-62.66%	-79.03%
FREE CASH FLOW
Cash From Operating Activities	-$3.700M	-$12.28M	-$14.09M
Capital Expenditures	-$10.00K	$0.00	-$170.0K
Free Cash Flow	-$3.690M	-$12.28M	-$13.92M
YoY Change	-70.67%	-17.65%	-32.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2016Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	81906000	USD
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3047000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	84953000	USD
CY2016Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	5200000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000	USD
CY2017Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	45157000	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	45022000	USD
CY2017Q1	us-gaap	Assets Assets	48312000	USD
CY2016Q4	us-gaap	Assets Assets	52906000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12860000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12378000	USD
CY2017Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	22541000	USD
CY2016Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	23353000	USD
CY2017Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	10135000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	10960000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	933000	USD
CY2017Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2017Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8904000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4862000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3000000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	79405000	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	185000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	689736000	USD
CY2017Q1	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	728096000	USD
CY2016Q4	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	715476000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1534000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1848000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	-36641000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48312000	USD
CY2017Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	10030000	USD
CY2016Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	9791000	USD
CY2017Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	44766000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	44559000	USD
CY2017Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	5200000	USD
CY2017Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3047000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56000	USD
CY2017Q1	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-18000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	693000	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	756000	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	373000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	209000	USD
CY2016Q1	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-37000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8048000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9244000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-622000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	634000	USD
CY2017Q1	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	7400000	USD
CY2016Q1	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	10000000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1535000	USD
CY2017Q1	us-gaap	Legal Fees LegalFees	3932000	USD
CY2016Q1	us-gaap	Legal Fees LegalFees	940000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	161498000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97688000	shares
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-500000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	314000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5606000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12934000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	693000	USD
CY2017Q1	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	31000	USD
CY2017Q1	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	713000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-314000	USD
CY2017Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-92000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3116000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	514000	USD
CY2016Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	912000	USD
CY2017Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-812000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17595000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12283000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2683000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2683000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	218000	USD
CY2016Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-337000	USD
CY2017Q1	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	525000	USD
CY2016Q1	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-9659000	USD
CY2017Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2620000	USD
CY2016Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	420000	USD
CY2016Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
CY2017Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	730000	USD
CY2016Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2017Q1	nwbo	Cash Cash Equivalents And Shortterm Investmentsperiod Increase Decrease CashCashEquivalentsAndShorttermInvestmentsperiodIncreaseDecrease	-4639000	USD
CY2016Q1	nwbo	Cash Cash Equivalents And Shortterm Investmentsperiod Increase Decrease CashCashEquivalentsAndShorttermInvestmentsperiodIncreaseDecrease	-10400000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	6871000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23048000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	2232000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12648000	USD
CY2017Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	713000	USD
CY2016Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2017Q1	us-gaap	Notes Assumed1 NotesAssumed1	205000	USD
CY2016Q1	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2017Q1	nwbo	Sharebased Compensation Aggregate Charges For Interest Associated With Accretion Of Our Convertible Notes Discount Net SharebasedCompensationAggregateChargesForInterestAssociatedWithAccretionOfOurConvertibleNotesDiscountNet	1300000	USD
CY2017Q1	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	78800000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	58278	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	108423	shares
CY2017Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	558	shares
CY2017Q1	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	3100	shares
CY2016Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.78
CY2017Q1	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.16
CY2017Q1	nwbo	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0.53
CY2017Q1	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.01
CY2017Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	9.28
CY2017Q1	nwbo	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	53803	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	126299000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48009000	shares
CY2017Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	34200000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	435000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	250000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	33515000	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32561000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	310000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	540000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	31711000	USD
CY2017Q1	us-gaap	Notes Payable NotesPayable	135000	USD
CY2017Q1	us-gaap	Interest Expense Other InterestExpenseOther	4000	USD
CY2016Q1	us-gaap	Interest Expense Other InterestExpenseOther	1000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1194000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	718000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	461000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	405000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	56000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	13000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10062000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	14104000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	713000	USD
CY2017Q1	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Granted FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantGranted	6194000	USD
CY2017Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-1439000	USD
CY2016Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	5200000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10062000	USD
CY2017Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	5200000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	14104000	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS INC
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185511822	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185511822	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157028270	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157028270	shares
CY2017Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	360000	USD
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q1	dei	Trading Symbol TradingSymbol	NWBO
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	191796437	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	5103000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2450000	USD
CY2017Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	310000	USD
CY2016Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	40000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	172000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	263000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	310000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.4pt; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">  </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of financial instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P3Y10M10D
CY2017Q1	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
CY2017Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2017Q1	nwbo	Class Of Warrants Or Rights Warrants Exercised For Cash ClassOfWarrantsOrRightsWarrantsExercisedForCash	3100000	shares
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	722000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	720000	USD
CY2017Q1	nwbo	Property Plant And Equipment Net Including Construction In Progress PropertyPlantAndEquipmentNetIncludingConstructionInProgress	45027000	USD
CY2016Q4	nwbo	Property Plant And Equipment Net Including Construction In Progress PropertyPlantAndEquipmentNetIncludingConstructionInProgress	44874000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7500000	USD
CY2017Q1	nwbo	Shares Issued During Period Shares Upon Exercise Of Warrants SharesIssuedDuringPeriodSharesUponExerciseOfWarrants	3100000	shares
CY2017Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	713000	USD
CY2017Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6200000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	135000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1535000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1206000	USD
CY2017Q1	nwbo	Refund Of Leashold Improvement Related To Uk Construction RefundOfLeasholdImprovementRelatedToUkConstruction	218000	USD
CY2016Q1	nwbo	Refund Of Leashold Improvement Related To Uk Construction RefundOfLeasholdImprovementRelatedToUkConstruction	0	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	31000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
CY2016Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2017Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	0	USD
CY2016Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	3644000	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	2000	USD
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2017Q1	nwbo	Stock Issued During Period Value Prior To Conversion Of Share Settled Debt StockIssuedDuringPeriodValuePriorToConversionOfShareSettledDebt	0	USD
CY2017Q1	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P3Y

Files In Submission

Name	View Source	Status
0001144204-17-027650-index-headers.html	Edgar Link	pending
0001144204-17-027650-index.html	Edgar Link	pending
0001144204-17-027650.txt	Edgar Link	pending
0001144204-17-027650-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nwbo-20170331.xml	Edgar Link	completed
nwbo-20170331.xsd	Edgar Link	pending
nwbo-20170331_cal.xml	Edgar Link	unprocessable
nwbo-20170331_def.xml	Edgar Link	unprocessable
nwbo-20170331_lab.xml	Edgar Link	unprocessable
nwbo-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466994_10q.htm	Edgar Link	pending
v466994_ex31-1.htm	Edgar Link	pending
v466994_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Q2 Form 10-Q Financial Statement

#000114420417027650 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Q2 Form 10-Q Financial Statement

#000114420417027650 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo